Can a New Prostate MRI Software Have an Impact?
Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.
In order to enhance the detection of clinically significant prostate cancer (csPCa), Cortechs.ai has launched OnQ Prostate, a post-processing software that may bolster prostate MRI interpretation through a proprietary diffusion-weighted imaging called restriction spectrum imaging (RSI).
Originally developed for brain cancer imaging, RSI reportedly increases the detection of aggressive cancer cells, according to Cortechs.ai. The company noted that research with the FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging.
The FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging, according to Cortechs.ai, the developer of the software. (Image courtesy of Cortechs.ai .)
In addition to improved accuracy with PI-RADS assessments, Cortechs.ai said the OnQ Prostate software offers a versatility that can enhance workflows with radiologists and referring providers by facilitating patient selection for biopsy procedures, treatment planning and post-treatment assessment.
“This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters so that more physicians and patients can benefit from this technology,” says Brittany Hunt, the head of prostate business development at Cortechs.ai.
Recent Videos
Related Content
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025Article
In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025Article
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025Article
In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025Article
The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
